Novo Partners for HF Cell Therapy
Novo Nordisk and Heartseed announced a global partnership and license agreement for the development, manufacturing, and commercialization of Heartseed’s lead asset HS-001. For context, Heartseed’s lead candidate, called HS-001, is an investigational cell therapy for the treatment of heart failure that uses purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). Below, FENIX provides highlights and insights from the press release.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.